BioPhage PA

Drug Profile

BioPhage PA

Alternative Names: BioPhage-PA

Latest Information Update: 23 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocontrol
  • Developer AmpliPhi Biosciences Corporation
  • Class Antibacterials; Bacteriophages; Viruses
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Otitis; Pseudomonal infections

Most Recent Events

  • 23 Sep 2015 No recent reports on development identified - Phase-I/II for Otitis in United Kingdom (Topical)
  • 23 Sep 2015 No recent reports on development identified - Phase-I/II for Pseudomonal infections in United Kingdom (Topical)
  • 31 Mar 2015 AmpliPhi Biosciences Corporation has patent protection for bacteriophage-based therapeutics in the Europe and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top